Comparative Studies Between Indian Regulatory Requirements and Global Benchmarks for Surgical Robots
COMPARATIVE STUDIES BETWEEN INDIAN REGULATORY REQUIREMENTS AND GLOBAL BENCHMARKS FOR SURGICAL ROBOTS
This journal article provides a comparative assessment of Indian regulatory requirements for surgical robots against established frameworks in the United States, European Union, and Japan. It evaluates parameters such as risk classification, pre-market approval pathways, clinical evidence requirements, quality management systems, software and AI governance, and post-market surveillance mechanisms. The study notes that while India classifies surgical robots as high-risk devices and aligns with IMDRF principles, significant gaps remain compared to global benchmarks.
Summary and content fields are drawn from the document text and are pending editorial review.
Who issued it
Who it governs
Researchers, medical device manufacturers, and policymakers should read this to understand the regulatory gaps and harmonization needs for surgical robots in India compared to global benchmarks.
What the document contains
The article evaluates regulatory domains for surgical robots including risk classification, pre-market approval pathways, clinical evidence requirements, quality management systems, software and AI governance, and post-market surveillance mechanisms across India, the USA, EU, and Japan.
The text does not provide binding regulatory rules, statutory enforcement measures, or direct legal mandates, functioning solely as an academic comparative study.
- India classifies surgical robots as Class C/D high-risk devices aligning with IMDRF and ISO 13485 principles.
- Global regulators in the USA, EU, and Japan maintain more stringent and structured approval pathways than India.
- Significant gaps remain in India's clinical evidence standards, software oversight, and post-market monitoring.
- Addressing regulatory gaps is essential for ensuring safe adoption and global competitiveness of robotic-surgical technologies in India.
· Abstract and Introduction · Methodology · Comparative Analysis of Regulatory Domains · Discussion on Gaps and Harmonization · Conclusion and References
How it scores
Each score is backed by a quote verified against the document text. Editorial review has not yet confirmed them.
Accountability
0/5Clear responsibility for AI outcomes
screening score · 2026-10-24
Fairness
0/5Non-discrimination and equitable treatment
screening score · 2026-10-24
Human Dignity
0/5Respect for the inherent worth of persons
screening score · 2026-10-24
Human Oversight
0/5Humans remain in control of consequential decisions
screening score · 2026-10-24
Privacy
0/5Protection of personal data and private life
screening score · 2026-10-24
Transparency
0/5Openness about how AI systems work and are used
screening score · 2026-10-24
Enforcement
3/5Consequences and compliance mechanisms with real force
Major jurisdictions such as India, USA, European Union, and Japan classify surgical robots as high-risk devices and require comprehensive evaluation.
Description
screening score · 2026-10-24
Impact Assessment
3/5Required assessment of an AI system's risks/impacts before or during use
The parameters evaluated included risk classification, pre-market approval pathways, clinical evidence requirements, quality management systems, software/AI governance, and post-market surveillance mechanisms.
Description
screening score · 2026-10-24